TECHNOLOGY
WORLD'S FIRST BRAIN AREA SPECIFIC BIOMARKER
Treating mental health disorders using data originating deep in the brain.
Simultaneous fMRI and EEG acquisitions
Advanced Statistical Models
Brain area-specific EEG-fMRI-Pattern (EFP) Biomarker
GMH's core technology is the first PTSD treatment based on a digital biomarker of brain activity associated with mental health disorders. The proprietary EEG-fMRI-Pattern (EFP) digital biomarker was developed by applying advanced statistical models to register amygdala fMRI data to EEG. This has never been done before.
The company's flagship product, Prism for PTSD, uses the amygdala-based biomarker because research has shown that PTSD is associated with hyperactivity of the amygdala, the center of our fight-flight response.
Prism for PTSD gathers years of neuroscience research and places it into the hands of mental healthcare providers. Combining an innovative software with an affordable FDA approved EEG headset for neurofeedback makes it is easy to integrate Prism into any clinic caring for PTSD patients. Designed for rapid deployment, the team is trained in the morning and patients can be treated the same afternoon.